Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 27 June 2017

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Chronic cough and gastroesophageal reflux disease

Researchers from Rochester, New York, find that 4 to 6 weeks of a proton-pump inhibitor successfully diagnoses and treats most patients with GERD-related cough.

News image

fiogf49gjkf04

In this study, researchers evaluated proton-pump inhibitor therapy, with or without a prokinetic agent, in the diagnosis and treatment of gastroesophageal reflux disease (GERD)-related cough.

The team performed a review of their experience of 214 patients with a cough of 3 weeks, referred over a 3 and a half year period.

The cough was eliminated or markedly improved in 86% of patients after 4 weeks.
Chest

Their findings are published in the March issue of Chest.

Overall, the team identified 183 patients with chronic cough, these were included in the study. However, 31 patients were disqualified because of abnormal chest radiographic findings, inadequate follow-up, or cough being not the primary complaint.

Of the 183 patients, 56 were identified as having GERD-related cough.

The team prescribed these patients a once-daily dose of a proton-pump inhibitor.

In addition, the team added a prokinetic agent if esophageal dysfunction was suspected, or response was inadequate.

Patients who did not respond underwent 24-hour esophageal pH monitoring.

The research team found that GERD was the single cause of cough in 43% of patients. A further 52% had GERD plus another cause, and 5% patients had GERD with more than 2 causes.

The team also determined that 43% of patients had a cough only, while 57% had other symptoms of GERD.

Overall, proton-pump therapy was successful in 79% of patients.

The team found that 24 patients responded to proton-pump inhibitor therapy, and 18 patients responded when metoclopramide or cisapride was added. The remaining 2 patients responded to a histamine type-2 blocker or cisapride alone.

The cough was eliminated or markedly improved in 86% of patients after 4 weeks, and by 8 weeks in the remaining 6 patients.

The team found that 6 of the nonresponders had aspiration diagnosed by bronchoscopy.

Additionally, 4 patients had fundoplication recommended, and 2 patients responded to alternative interventions.

Drs Robert Poe and Michael Kallay concluded, "4 to 6 weeks of a proton-pump inhibitor alone or in combination with a prokinetic agent successfully diagnoses and treats 4 of 5 patients with GERD-related cough".

"24-hour esophageal pH monitoring will confirm the diagnosis in the others."

"These patients may be candidates for fundoplication."

"Nonresponders often aspirate as an additional aggravating factor."

Chest 2003; 123: 679-84
14 March 2003

Go to top of page Email this page Email this page to a colleague

 27 June 2017 
Health-related quality of life in eosinophilic esophagitis
 27 June 2017 
Extraintestinal manifestations of IBD
 27 June 2017 
Viral cancers in Barrett’s
 26 June 2017 
Anger in HIV-HCV co-infected patients
 26 June 2017 
Iron and IBD risk
 26 June 2017 
Weight loss for low-income postpartum women
 23 June 2017 
Treatment for KRAS wild-type advanced colorectal cancer
 23 June 2017 
Epidemiology of Hep E
 23 June 2017 
Predictive model for clinical course of Crohn's disease
 22 June 2017 
Vonoprazan-based triple therapy on H. pylori eradication
 22 June 2017 
Adolescent transition in IBD
 22 June 2017 
Patient understanding of biologic therapy in IBD
 21 June 2017 
Statins in chronic Hep C
 21 June 2017 
Racial disparities in colorectal cancer
 21 June 2017 
Hydrolyzed wheat flour improves immunogenicity in celiac disease
 20 June 2017 
Therapies in chronic pancreatitis
 20 June 2017 
Genetic analyses for malignancy detection in biliary strictures
 20 June 2017 
Viral-associated esophagus cancers
 19 June 2017 
Global prevalence of IBS in adults
 19 June 2017 
Clinical improvement in mild acute pancreatitis
 19 June 2017 
Repeat biopsy and celiac disease outcomes 
 16 June 2017 
Exercise-induced GI syndrome—implications for intestinal disease
 16 June 2017 
HCV among reproductive-aged women and children in the USA
 16 June 2017 
Adverse events after outpatient colonoscopy
 15 June 2017 
Pioglitazone for NASH
 15 June 2017 
Treatment of eosinophilic esophagitis
 15 June 2017 
Urinary adverse events after rectal cancer treatment
 14 June 2017 
Genetics of familial colorectal cancer
 14 June 2017 
Abdominal ultrasound in blunt torso trauma
 14 June 2017 
Acute kidney injury in Hep C and sofosbuvir-based regimens
 13 June 2017 
Serrated polyps in the colon and rectum
 13 June 2017 
Colorectal cancer during pregnancy
 13 June 2017 
Biomarker for penetrating Crohn's
 12 June 2017 
Course of primary sclerosing cholangitis
 12 June 2017 
Quality of life in end-stage liver disease
 12 June 2017 
Clinical remission in patients with Crohn's disease
 09 June 2017 
Socioeconomic influences on H. pylori gastritis
 09 June 2017 
Celiac disease in Ireland
 09 June 2017 
Consultants do not follow up on GI tests they recommend
 08 June 2017 
Genetics and the gut microbiota and metabolic syndrome
 08 June 2017 
Antireflux surgery in extraesophageal reflux
 08 June 2017 
Breath testing in gastrointestinal disorders
 07 June 2017 
Multidisciplinary care and liver cancer
 07 June 2017 
Model for excluding NAFLD
 07 June 2017 
Hospital readmission in IBD
 06 June 2017 
Dietary patterns and colorectal cancer risk
 06 June 2017 
Direct-acting antiviral agents for HCV
 06 June 2017 
Medical therapies for stricturing Crohn’s
 05 June 2017 
Hospital-acquired conditions in Crohn’s disease
 05 June 2017 
Celiac disease prevalence in the USA
 05 June 2017 
Depression and IBD
 02 June 2017 
Menopausal hormone therapy and fecal incontinence
 02 June 2017 
Narcotic and corticosteroid prescriptions in IBD
 02 June 2017 
Treating anemia after gastrectomy
 01 June 2017 
Infliximab and cancer in pediatric IBD
 01 June 2017 
Health insurance policies in IBD
 01 June 2017 
Endoscopic quality improvement program for polyp detection
 31 May 2017 
Probiotics and Clostridium difficile infection
 31 May 2017 
Post-procedural adverse events after colonoscopy
 31 May 2017 
Clinical decision-making in severe alcoholic hepatitis

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us